Summary Interleukin 4 (IL-4) suppresses the interleukin 2 (IL-2) induced lymphokine-activated killer (LAK) cell development from human peripheral blood mononuclear cells (PBMC). Suppression is observed at high (1,000 U ml-') as well as low (10 U ml-') concentrations of IL-2. IL-4 needs to be present at the beginning of the IL-2 culture to exert the suppressive effect. IL-4 also inhibits the development of CD25 (Tac) antigen on the PBMC cultured in IL-2. Interleukin I (IL-1) can reverse the suppressive effect of IL-4 on LAK induction when added at the early phase of the IL-2 culture. IL-I enhances IL-2 induced LAK development, which may partially explain the reversion of IL-4 inhibition by IL-1. IL-1 also reverses the inhibitory effect of IL-4 on the development of CD25 antigen expression, although IL-1 alone does not enhance the induction of CD25 expression in PBMC cultured by IL-2. Furthermore, IL-4 suppresses IL-2 induced IL-1 production in PBMC. Thus, suppression of CD25 may be a pathway for the suppression of LAK induction. The expression of CD56 is not directly associated with the expression of LAK activity. IL-4, IL-1 or combination of the two cytokines has no effect on IL-2 induced expression of CD56. These results indicate that IL-4 has an antagonistic effect and IL-1 has a synergistic effect on IL-2-induced LAK development.
Interleukin 4 (IL-4) has pleiotropic regulatory effects on components of immune system including resting B cells, macrophages, mast cells, thymocytes (Gause et al., 1988) and peripheral T cells (Brown et al., 1988; Kern et al., 1988) . Murine IL-4 can induce lymphokine activated killer (LAK) function (Mule et al., 1987; Peace et al., 1988) and also acts synergistically with interleukin 2 (IL-2) in LAK development (Mule et al., 1989) . With human cells, IL-4 suppresses IL-2 induced LAK development (Widmer et al., 1987; Spits et al., 1988) even though IL-4 augments mixed lymphocytes culture (MLC) induced development of antigen-specific cytotoxic T lymphocytes (CTL) (Spits et al., 1988) , influenza virus specific CTL induction (Horohov et al., 1988) and growth of human tumour-infiltrating lymphocytes by IL-2 (Kawakami et al., 1988) .
Recently, it has been shown that IL-4 inhibits the secretion of interleukin 1 (IL-1) from macrophages (Essner et al., 1989) , and IL-1 has been reported to promote IL-2 dependent LAK development (Crump et al., 1989) . Therefore, we sought to define the manner in which IL-4 can suppress IL-2 induced LAK induction, and to determine if IL-1 can reverse the IL-4 mediated suppression of LAK induction. To approach these questions, we examined the effect these cytokines on modulation of cytotoxicity and on the expression of IL-2 activation markers such as CD25 (Tac) and CD56 (NKH1).
Materials and methods
Cell preparation and tymphocyte culture Human peripheral blood mononuclear cells (PBMC) Spontaneous release was determined from wells containing no effector cells and total release was obtained from wells containing target cells lysed by 5% NP40 detergent. Each assay was done in triplicate. Each experiment was performed with four different effector cell/target cell ratios (E/T ratios). The per cent lysis of four E/T ratios within each experiment were used to obtain a target cell survival curve and to calculate lytic units (LU) by exponential fit (Pross et al., 1981 rin conjugated) specific for CD56 were obtained fron, Coul- ter Immunology (Hialeah, FL, USA). Cells were incubated with both antibodies for 30 min at 4°C, then washed three times with PBS containing 2% normal bovine albumin and 0.02% sodium azide. The proportion of cells reacting with MoAb was determined by two colour flow cytometric analysis with a EPIC IV flow cytometer (Coulter).
IL-I concentrations of supernatants from IL-2 and/or IL-4 cultures were determined by EIA with an assay kit following the manufacture's instruction (Cistron, Pine Brook, NJ, USA). Each assay was done in duplicate.
Results
Effects of IL-4 on the induction of LAK activity To examine the effect of IL-4 on the induction on LAK activity, PBMC were cultured with 50 U ml1' of IL-2 for 4 days in the presence of various concentrations of IL-4. Cytotoxicity was measured against M 14 targets and the results of two experiments are shown in Table I . Although there is variation from one experiment to another in the degree of suppression mediated by a given concentration of IL-4, IL-4 from 10 to 100 U ml-' inhibited LAK induction in a dose dependent manner. We chose 50 U ml-' of IL-4 as the standard concentration that would give substantial suppression. LAK induction appears to be more sensitive to IL-4 regulation at low dose of IL-2, but 50 U ml-' of IL-4 is suppressive to LAK development over a wide range of IL-2 concentrations up to 1,000 U ml-' (Figure 1 ). Based on these results, we used 50 U ml-' as our standard IL-2 concentration.
In order to determine when IL-4 acts on LAK induction, 50 U ml-' of IL-4 was serially added to replicate 4 day cultures of PBMC and IL-2 ( Figure 2 ). The inhibitory effect was observed only when IL-4 was added at the initiation of LAK induction. When IL-4 was added 24 h or more after IL-2, no significant inhibition was observed. (Siegel et al., 1987) and CD56 (Ramsdell et al., 1988) . Therefore, we examined the effect of IL-4 on the expression of these two activation markers to determine whether IL-4 can influence these IL-2 induced changes. PBMC were incubated with 50 U ml-1 of IL-2 in the absence or presence of 50 U ml-' of IL-4. Aliquots were harvested on day 4 of culture, stained with monoclonal antibodies, and analysed by flow cytometry. Results of three experiments are shown in Table II . Our data show that IL-4 suppresses the IL-2 induced expression of CD25. These data also show that IL-4 has no effect on the total proportion of cells staining with anti-CD56, while the intensity of both CD56 and CD25 staining is reduced by IL-4.
Antagonistic effect of IL-I on IL-4 mediated inhibition IL-4 inhibits the secretion of interleukin 1 (IL-1) from macrophages (Essner et al., 1989) . Therefore, it is possible that IL-4 inhibition of LAK is mediated through an effect on IL-1 production. To address this possibility, we assessed the effect of IL-4 on IL-l-enhanced LAK development. We also investigated whether IL-1 can abrogate the IL-4 mediated suppression of LAK development. PBMC were incubated with 50 U ml-' of IL-2 with or without 50 U ml-' of IL-4. Various amounts of IL-I were added to the media at the initiation of the culture. The results in Table III confirm previous reports (Crump et al., 1989) Table IV . IL-1 augmented LAK activity as late as 72 h after the culture was started and the addition of IL-1 at 24 h showed optimal enhancement of LAK activity. Again, the LAK activity enhanced by IL-1 was suppressed by IL-4. It is of interest that IL-4 is least suppressive at the time point when IL-1 shows optimal synergism with IL-2.
We also investigated the effect of IL-1 on CD25 and CD56 expression. Table V shows experiments where IL-1 partially abrogated the suppression of CD25 expression by IL-4. While IL-1 alone enhances the LAK induction of IL-2 cultured PBMC as shown above, it does not synergise with IL-2 in inducing CD25 expression. Despite their regulatory effects on LAK induction, neither IL-4 nor IL-1 modulates the percentage of CD56+ cells in IL-2 culture. In experiment 1 (Table V) , we examined the intensity of CD56 expression. PBMC were incbated with 50 U ml' of rIL-2 with or without 50 U ml' of rIL-4. Aliquots were harvested at the day 4 and then phenotypic analysis was performed. N.E., not examined. 16.6 ± 3.9 100 U ml-' of rIL-I3 was serially added to replicate 4 day cultures of PBMC and IL-2 (50 U ml-') with or without rIL-4 (50 U ml-'). The values represent LU per 106 cells ± s.d. PBMC incubated with IL-2 stained with anti-CD56 antibody at a peak channel at 27. While IL-1 alone increases (peak channel at 40) and IL-4 reduces (peak channel at 24) the intensity of CD56 expression, IL-1 does not abrogate the IL-4 mediated suppression of CD56 intensity (peak channel at 21). We have also tested the effect of IL-4 on IL-2 induced IL-1 production. PBMC were cultured in IL-2 for 4 days and the cells were tested for LAK activity while their culture supernatants were tested for IL-1-beta. Results from Table VI show that IL-4 not only suppresses LAK cytotoxicity but also significantly decreases IL-2 induced IL-1 production. PBMC were cultured with indicated cytokines for 4 days; the cultured cells were tested for LAK cytotoxicity against M 14 and the culture supernatants were tested for IL-1 concentration by EIA. Discussion IL-4 inhibits the IL-2 induced LAK development of human PBMC (Widmer et al., 1987; Spits et al., 1988) . Our data not only support these previous reports, but also show that suppression of LAK is dependent on the dose of IL-4 (Table  I) , and the suppression is effective over wide range of IL-2 concentration ( 10-1,000 U ml-') ( Figure 1 ).
IL-4 added more than 24 h after the initiation of IL-2 culture does not suppress LAK induction (Figure 2) . Similarly, other irvestigators have reported that IL-4 suppresses LAK development only at the initiation of the IL-2 culture (Spits et al., 1988) . has also been reported to inhibit the activation of NK cells induced by short-term (18 h) incubation with IL-2 without any involvement of regulatory cells (Nagler et al., 1988) . This is in marked contrast to the effect of IL-4 in enhancing MLC induced CTL induction or influenza virus specific CTL induction. These effects are more profound if IL-4 is added at the later phase of incubation (Horohov et al., 1988; Widmer et al., 1987 One candidate for an early event sensitive to IL-4 suppression would be the induction of IL-2 receptors (CD25). Therefore, we tested the effects of IL-4 on CD25 and CD56 expression. IL-4 suppresses the IL-2 induced expression of CD25 but not CD56 (Table II) . These data confirmed the report of Brooks and Rees (1988) that IL-4 suppresses the IL-2 induced expression of CD25 in both percentage of positive cells and intensity of staining. In contrast, our results indicate that the IL-4 does not suppress the percentage of IL-2 induced CD56 expressing cells, but does reduce the intensity of CD56 expression. This suggests that inhibition of CD56 or CD25 expression may be a mechanism by which IL-4 inhibits LAK activity.
An alternative early event that might be affected by IL-4 might be IL-I production. Recently, it has been shown that IL-4 inhibits the secretion of interleukin 1 (IL-1) from macrophages (Essner et al., 1989) . This suggests that IL-4 mediated inhibition on LAK induction may be through the suppression of IL-1 production triggered by IL-2. As shown in the Tables III-V, IL-1 and IL-4 have antagonistic effects on some IL-2 induced PBMC responses. IL-1 promotes LAK development in a dose-dependent manner, while IL-4 suppresses this function (Table III) . Synergism in LAK development by IL-1 is most effective 2 days after initiation of the culture and IL-4 is most suppressive when present from the beginning of the culture (Table IV) . In other words, IL-4 is least suppressive at the point when IL-1 shows its most significant enhancement of LAK development. More importantly our data directly show that IL-4 can suppress IL-2 induced IL-1 production in PBMC (Table VI) . These results strongly suggest that IL-4 mediated suppression of IL-1 production may contribute to the inhibition of LAK induction.
We postulated that CD25 modulates the late phase of LAK development but is not involved in the early phase of LAK induction (Shau & Golub, 1985) . Differences in timing might explain the apparently divergent results with anti-CD25 antibodies which have been found to have either no effect on LAK induction (Tsudo et al., 1987) or to cause a partial blocking of LAK induction (Grimm et al., 1983; Shau et al., 1988) . While the inhibition of LAK cytotoxicity by anti-CD25 is often marginal and much less pronounced than the inhibition of IL-2 induced lymphocyte proliferation (Siegel et al., 1987) , the combination of anti-CD25 and antibodies specific for IL-2R-beta chain caused much greater inhibition of LAK than the latter alone (Phillips et al., 1989) . This evidence suggests that CD25 does have some importance in the generation of LAK function. IL4 suppresses CD25 expression but the suppression can be partially reversed by IL-1. This result, combined with the fact that IL-1 can reciprocally regulate LAK function with IL-4, indicates that suppression of CD25 expression and/or reduced IL-1 production are likely to be involved in suppression of LAK development. Neither cytokine alone or in combination changes the percentage of CD56+ cells. However, IL-4 reduces and IL-1 enhances the intensity of CD56 expression individually. While IL-1 cannot reverse the IL-4 mediated suppression of CD56 intensity, it can partially reverse the suppression of cytotoxicity. Therefore, these data suggest that the expression of CD56 does not directly correlate the development of LAK activity. Our results in this study clearly indicate that IL-2 induced PBMC responses are subject to regulation by other cytokines. IL-1 and IL-4 have reciprocal effects of LAK development by IL-2, with IL-1 augmenting and IL-4 suppressing cytotoxicity.
